A
Angelika Hammerer-Lercher
Researcher at Innsbruck Medical University
Publications - 93
Citations - 2367
Angelika Hammerer-Lercher is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Natriuretic peptide & Myocardial infarction. The author has an hindex of 23, co-authored 86 publications receiving 1919 citations. Previous affiliations of Angelika Hammerer-Lercher include University Hospital of Basel & University of Innsbruck.
Papers
More filters
Journal ArticleDOI
The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure.
TL;DR: It could be demonstrated that in chronic heart failure patients and during the subacute phase of myocardial infarction, the cardiac natriuretic peptides were best markers to identify heart failure and the most powerful predictors of morbidity and mortality.
Journal ArticleDOI
Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction.
Angelika Hammerer-Lercher,Elke Neubauer,Silvana Müller,Otmar Pachinger,Bernd Puschendorf,Johannes Mair +5 more
TL;DR: In this paper, the authors measured brain natriuretic peptide (BNP), NT-proBNP, and Pro-atrial natriive peptide(NT-proANP) for the detection of heart failure.
Journal ArticleDOI
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM
Michel Langlois,Børge G. Nordestgaard,Anne Langsted,M. John Chapman,Kristin M. Aakre,Hannsjörg Baum,Jan Borén,Jan Borén,Eric Bruckert,Alberico L. Catapano,Christa M. Cobbaert,Paul Collinson,Olivier S. Descamps,Christopher J. Duff,Arnold von Eckardstein,Angelika Hammerer-Lercher,Pia R. Kamstrup,Genovefa Kolovou,Florian Kronenberg,Samia Mora,Kari Pulkki,Alan T. Remaley,Nader Rifai,Emilio Ros,Emilio Ros,Sanja Stankovic,Ana Stavljenić-Rukavina,Grazyna Sypniewska,Gerald F. Watts,Olov Wiklund,Olov Wiklund,Päivi Laitinen +31 more
TL;DR: Residual risk of ASCVD even under optimal LDL-lowering treatment should be also assessed by non-HDLC or apolipoprotein B (apoB), especially in patients with mild-to-moderate hypertriglyceridemia (2–10 mmol/L).
Journal ArticleDOI
Analysis of Circulating Forms of proBNP and NT-proBNP in Patients with Severe Heart Failure
Angelika Hammerer-Lercher,Bernhard Halfinger,Bettina Sarg,Johannes Mair,Bernd Puschendorf,Andrea Griesmacher,Norberto A. Guzman,Herbert Lindner +7 more
TL;DR: The higher molecular masses for NT-proBNP and proBNP observed in the Western blotting analyses than those expected from calculations can be explained by O-glycosylation of these peptides in vivo.
Journal ArticleDOI
Natriuretic Peptides as Markers of Mild Forms of Left Ventricular Dysfunction: Effects of Assays on Diagnostic Performance of Markers
Angelika Hammerer-Lercher,Wilma Ludwig,Gerda Falkensammer,Silvana Müller,Elke Neubauer,Bernd Puschendorf,Otmar Pachinger,Johannes Mair +7 more
TL;DR: The performance of BNP for the diagnosis of systolic or diastolic LVD is not affected by the assay used, whereas the performance of NT-proBNP for thediagnosis of isolated diastolics LVA is assay dependent.